Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-05-08 | Mr. Gregory Thomas LucierIndependent Director | 10,00k | 83,20k | Kauf | 8,32 | 60,00k | 20,00% |
| 2026-05-01 | Mr. Simon P. DingemansIndependent Director | 25,00k | 203,50k | Kauf | 8,14 | 31,23k | 401,61% |
| 2026-03-10 | Mr. Sanjeev Kishen MehraIndependent Director | 125,00k | 1,00M | Kauf | 8,01 | 475,00k | 35,71% |
| 2026-02-23 | Mr. R. Brent JonesInsider | -2,81k | 24,94k | Sale to Issuer | 8,89 | 39,95k | -6,56% |
| 2026-02-23 | Mr. Claudius O. SokenuExec. VP, Corporate Secretary and Chief Legal & Compliance Officer | -2,38k | 21,12k | Sale to Issuer | 8,89 | 16,89k | -12,33% |
| 2026-02-23 | Mr. Steven W. EckSenior VP, Interim CFO, Corporate Controller & CAO | -2,47k | 22,05k | Sale to Issuer | 8,89 - 9,11 | 99,33k | -2,43% |
| 2026-02-23 | Mr. Benoit GourdierExec. VP of Bioscience Production | -3,03k | 26,93k | Sale to Issuer | 8,89 | 24,86k | -10,86% |
| 2026-02-23 | Ms. Brittany HankamerExec. VP & Chief HR Officer | -1,68k | 15,04k | Sale to Issuer | 8,89 - 9,11 | 249,05k | -0,67% |
| 2026-02-19 | Mr. Gregory Thomas LucierIndependent Director | 50,00k | 458,00k | Kauf | 9,16 | 50,00k | - |
| 2026-02-20 | Mr. Steven W. EckSenior VP, Interim CFO, Corporate Controller & CAO | -2,13k | 19,19k | Sale to Issuer | 9,03 | 101,80k | -2,04% |
| 2026-02-20 | Ms. Brittany HankamerExec. VP & Chief HR Officer | -1,45k | 13,12k | Sale to Issuer | 9,03 | 250,73k | -0,58% |
| 2026-02-20 | Mr. Claudius O. SokenuExec. VP, Corporate Secretary and Chief Legal & Compliance Officer | -2,92k | 26,36k | Sale to Issuer | 9,03 | 19,27k | -13,16% |
| 2026-02-20 | Mr. Corey D. WalkerPresident of Laboratory Solutions | -4,96k | 44,82k | Sale to Issuer | 9,03 | 16,02k | -23,65% |
| 2026-02-20 | Mr. R. Brent JonesInsider | -9,51k | 85,84k | Sale to Issuer | 9,03 | 34,20k | -21,75% |
| 2026-02-20 | Mr. Benoit GourdierExec. VP of Bioscience Production | -4,16k | 37,56k | Sale to Issuer | 9,03 | 19,33k | -17,71% |
| 2026-02-12 | Mr. Gregory L. SummeIndependent Chairman of the Board | 100,00k | 940,00k | Kauf | 9,40 | 441,01k | 29,32% |
| 2025-12-05 | Mr. Sanjeev Kishen MehraIndependent Director | 350,00k | 3,88M | Kauf | 11,09 | 350,00k | - |
| 2025-11-17 | Mr. Emmanuel LignerPresident, CEO & Director | 87,50k | 993,13k | Kauf | 11,35 | 87,50k | - |
| 2025-10-30 | Mr. Gregory L. SummeIndependent Chairman of the Board | 100,00k | 1,13M | Kauf | 11,25 | 341,01k | 41,49% |
| 2025-10-02 | Mr. Benoit GourdierExec. VP of Bioscience Production | -1,26k | 17,41k | Sale to Issuer | 13,77 | 11,58k | -9,84% |
| 2025-08-21 | Mr. Gregory L. SummeIndependent Chairman of the Board | 100,00k | 1,26M | Kauf | 12,56 | 241,01k | 70,92% |
| 2025-08-14 | Ms. Brittany HankamerExec. VP & Chief HR Officer | -181,00 | 2,35k | Sale to Issuer | 12,98 | 171,56k | -0,11% |
| 2025-08-05 | Mr. Steven W. EckSenior VP, Interim CFO, Corporate Controller & CAO | -3,48k | 39,59k | Verkauf | 11,39 | 55,07k | -5,94% |
| 2025-07-31 | Mr. Steven W. EckSenior VP, Interim CFO, Corporate Controller & CAO | -1,39k | 18,61k | Sale to Issuer | 13,44 | 58,54k | -2,31% |
| 2025-07-24 | Mr. Claudius O. SokenuExec. VP, Corporate Secretary and Chief Legal & Compliance Officer | -3,12k | 43,75k | Sale to Issuer | 14,01 | 15,04k | -17,19% |
| 2025-06-21 | Mr. Corey D. WalkerPresident of Laboratory Solutions | -2,73k | 37,05k | Sale to Issuer | 13,57 | 6,69k | -28,99% |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
